NI201400003A - Una nueva composición terapéutica que contiene apomorfina como ingrediente activo - Google Patents

Una nueva composición terapéutica que contiene apomorfina como ingrediente activo

Info

Publication number
NI201400003A
NI201400003A NI201400003A NI201400003A NI201400003A NI 201400003 A NI201400003 A NI 201400003A NI 201400003 A NI201400003 A NI 201400003A NI 201400003 A NI201400003 A NI 201400003A NI 201400003 A NI201400003 A NI 201400003A
Authority
NI
Nicaragua
Prior art keywords
composition containing
active ingredient
therapeutic composition
new therapeutic
containing apomorphine
Prior art date
Application number
NI201400003A
Other languages
English (en)
Inventor
Dey Michael
Richard Joel
Baronnet Marie-Madeleine
Mondoly Nathalie
Bertocchi Laurent
Harnett Jeremiah
Original Assignee
Britannia Pharmaceticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceticals Ltd filed Critical Britannia Pharmaceticals Ltd
Publication of NI201400003A publication Critical patent/NI201400003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

La presente invención se refiere a una composición farmacéutica que contiene apomorfina como principio farmacéutico activo, codisolvente, antioxidante, agua con un PH mayor que 4. La fórmulación farmacéutica es adecuada para la administración parenteral para el tratamiento de la enfermedad de Parkinson.
NI201400003A 2011-07-11 2014-01-09 Una nueva composición terapéutica que contiene apomorfina como ingrediente activo NI201400003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11290320A EP2545905A1 (en) 2011-07-11 2011-07-11 A new therapeutical composition containing apomorphine as active ingredient

Publications (1)

Publication Number Publication Date
NI201400003A true NI201400003A (es) 2015-10-12

Family

ID=46514305

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400003A NI201400003A (es) 2011-07-11 2014-01-09 Una nueva composición terapéutica que contiene apomorfina como ingrediente activo

Country Status (29)

Country Link
US (4) US11026938B2 (es)
EP (2) EP2545905A1 (es)
JP (2) JP6356064B2 (es)
KR (1) KR101990897B1 (es)
CN (2) CN103826612B (es)
AU (1) AU2012283381B2 (es)
BR (1) BR112014000306B1 (es)
CA (1) CA2841807C (es)
CL (1) CL2014000050A1 (es)
CO (1) CO6870038A2 (es)
CR (1) CR20140005A (es)
CU (1) CU24159B1 (es)
DO (1) DOP2014000003A (es)
EA (1) EA025870B1 (es)
EC (1) ECSP14013200A (es)
GE (1) GEP20196969B (es)
GT (1) GT201400003A (es)
IL (1) IL230308A (es)
IN (1) IN2014DN00090A (es)
MA (1) MA35411B1 (es)
MX (2) MX2014000454A (es)
MY (1) MY168212A (es)
NI (1) NI201400003A (es)
PE (1) PE20141539A1 (es)
SG (1) SG10201605491PA (es)
TN (1) TN2014000001A1 (es)
UA (1) UA113962C2 (es)
WO (1) WO2013007381A1 (es)
ZA (1) ZA201309711B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
ES2715028T3 (es) * 2012-06-05 2019-05-31 Neuroderm Ltd Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
RU2017123762A (ru) * 2014-12-23 2019-01-24 Нейродерм Лтд Кристаллические формы апоморфина и их применение
MA43042A (fr) * 2015-09-28 2018-08-08 Ever Neuro Pharma Gmbh Composition aqueuse d'apomorphine pour une administration sous-cutanée
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
EP4009973A4 (en) * 2019-08-07 2023-08-23 Aclipse One, Inc. PHARMACEUTICAL COMPOSITIONS OF (6AS) -6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL
WO2021235436A1 (ja) 2020-05-20 2021-11-25 株式会社メドレックス アポモルヒネ含有経皮吸収型製剤
WO2022271537A1 (en) * 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1662566A1 (ru) * 1988-03-05 1991-07-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ стабилизации инъекционного раствора апоморфина
JP2822049B2 (ja) * 1989-02-02 1998-11-05 ゼリア新薬工業株式会社 水性製剤組成物
PT689438E (pt) * 1993-03-26 2003-10-31 Franciscus Wilhelmus He Merkus Composicoes farmaceuticas para administracao intranasal de apomorfina
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en) 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6939094B2 (en) 2003-01-28 2005-09-06 Macro Technologies Inc. Autonomous power interface for modifying limited rotation speed of a machine
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
BRPI0711796A2 (pt) 2006-05-24 2011-12-06 Bayer Schering Pharma Aktiendesellschaft anticorpos de bloqueio de função de integrinas anti-alfa5beta1 humanos e humanizados com imunogenicidade reduzida
US20080171072A1 (en) * 2006-08-11 2008-07-17 Frank Burczynski Ocular inserts containing apomorphine
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient

Also Published As

Publication number Publication date
MX2014000454A (es) 2014-09-01
GT201400003A (es) 2017-09-28
US11026938B2 (en) 2021-06-08
BR112014000306A2 (pt) 2017-02-07
IL230308A (en) 2017-04-30
KR20140072861A (ko) 2014-06-13
US20180098981A1 (en) 2018-04-12
IN2014DN00090A (es) 2015-05-15
SG10201605491PA (en) 2016-08-30
WO2013007381A1 (en) 2013-01-17
MX2021010046A (es) 2021-09-21
JP2014518285A (ja) 2014-07-28
EA025870B1 (ru) 2017-02-28
CU24159B1 (es) 2016-03-31
EA201400067A1 (ru) 2015-02-27
CL2014000050A1 (es) 2014-08-18
US11766431B2 (en) 2023-09-26
CU20140005A7 (es) 2014-04-24
JP6356064B2 (ja) 2018-07-11
CN103826612B (zh) 2020-07-28
CA2841807A1 (en) 2013-01-17
ZA201309711B (en) 2014-08-27
BR112014000306B1 (pt) 2022-03-29
CA2841807C (en) 2018-02-20
EP2545905A1 (en) 2013-01-16
EP2731589A1 (en) 2014-05-21
MA35411B1 (fr) 2014-09-01
JP2017081947A (ja) 2017-05-18
UA113962C2 (xx) 2017-04-10
US20140128422A1 (en) 2014-05-08
PE20141539A1 (es) 2014-10-25
CR20140005A (es) 2014-07-21
MY168212A (en) 2018-10-15
TN2014000001A1 (en) 2015-07-01
CN103826612A (zh) 2014-05-28
CO6870038A2 (es) 2014-02-20
AU2012283381A1 (en) 2014-02-06
DOP2014000003A (es) 2014-06-01
ECSP14013200A (es) 2014-04-30
CN108434094A (zh) 2018-08-24
AU2012283381B2 (en) 2017-07-27
US20210244724A1 (en) 2021-08-12
KR101990897B1 (ko) 2019-06-19
US20160310480A1 (en) 2016-10-27
GEP20196969B (en) 2019-04-25

Similar Documents

Publication Publication Date Title
NI201400003A (es) Una nueva composición terapéutica que contiene apomorfina como ingrediente activo
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
BR112012023021A2 (pt) compostos de indazol e seus usos
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
ECSP14013155A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
EA201490573A1 (ru) Соединение бензотиазолона
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112015019307A2 (pt) derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada
NI201200196A (es) Agentes terapéuticos 976
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
BR112015004127A2 (pt) sais de composto benzotiazolona como agonista de beta-2-adrenorreceptor
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
DOP2014000302A (es) Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal